Literature reported dysregulation of miR-591 confer paclitaxel resistance to ovarian cancer (Huh et al., 2013), and circ_0091581 could promote the progression of hepatocellular carcinoma through miR-591/FOSL2 Axis (Ji et al., 2021). Here, FOSL2 is linked to ovarian cancer.